EQUITY RESEARCH MEMO
RS Medical
Generated 5/11/2026
Executive Summary
Conviction (model self-assessment)65/100
RS Medical is a US-based private medical device company specializing in prescription-grade electrotherapy devices for chronic pain management and muscle rehabilitation. Founded in 1990, the company's flagship product, the RS-4i Plus, utilizes patented Intersperse technology to combine Interferential Therapy (IFT) and Neuromuscular Electrical Stimulation (NMES). With over 1.5 million patients treated, RS Medical has established a strong foothold in the home-use electrotherapy market. The company's products are prescribed by healthcare providers for conditions such as chronic musculoskeletal pain, offering non-invasive, drug-free relief.
Upcoming Catalysts (preview)
- Q4 2026FDA Clearance for Next-Generation RS-4i Device70% success
- Q2 2027Expansion into International Markets (EU/Asia)50% success
- Q3 2026Strategic Partnership for Distribution with Major Orthopedic Group60% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)